The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.
about
alpha-Synuclein and neuronal cell deathInhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compoundsAlpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recyclingInteractions between fatty acids and alpha-synucleinNeuropharmacological review of the nootropic herb Bacopa monnieriProtein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseasesDynamic structural flexibility of α-synucleinBreaking the Code of Amyloid-β OligomersFunction and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescenceAlpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body DisordersDietary factors in the etiology of Parkinson's disease.The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's diseaseAltered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathiesSolid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-SynucleinDisease-toxicant interactions in Parkinson's disease neuropathologyTotal α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA.Acyl coenzyme A thioesterase 7 regulates neuronal fatty acid metabolism to prevent neurotoxicity.A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brainα-Synuclein oligomers impair neuronal microtubule-kinesin interplay.Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Interaction of huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's disease.Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cellsModulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Amyloidogenesis abolished by proline substitutions but enhanced by lipid binding.Copper-triggered aggregation of ubiquitin.Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopyalpha-Synuclein abnormalities in mouse models of peroxisome biogenesis disorders.Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathiesLipid classes and fatty acid patterns are altered in the brain of γ-synuclein null mutant mice.Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's diseaseUbiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5).Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's DiseaseDrosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation.Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy.Recent advances in the genetics of Parkinson's disease.Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome.The regulation of catalase activity by PPAR γ is affected by α-synuclein.
P2860
Q21202835-EFDDAC30-D003-4B9D-916F-4CDD3529DD0FQ24298231-DFCA78D0-1343-4DBE-B0A1-75E0521DAB3AQ24311523-244508C1-2C3F-4969-9D47-9B71FE2F59BDQ24336967-8D693078-6FB2-43A5-9511-13858625F8BBQ24630774-5FECBA77-E981-4CC1-BAB2-327C65E34B69Q24650014-B97832BE-5259-43AC-85FD-2F384777BC65Q26770060-771DB99B-6513-430C-8EBA-59351486D090Q26862630-48AF624A-EB92-4FA0-AFB8-00DE4D353149Q27026292-461BABD6-70EF-4BC2-B456-92E503104B2FQ28067429-FCE0C9FF-3D1A-4D17-9332-C8319F1C04D2Q28085390-4E97709A-C7D3-47A3-8615-1DAD13B00CCAQ28087330-BA4EBD59-5E2F-4B68-8D30-557760CE74D3Q28591852-DDEC3C7D-8B4F-45C6-8E40-83A956726788Q28817941-4485F3B3-CE85-4E27-A444-5FEBC9697477Q29248297-EBA807EA-299A-441E-A608-E8D518D1E6E5Q30392912-90837A0C-3EA7-438C-B7CB-05D5565B6C63Q30447826-1298ECF2-86E7-43C6-9052-4063AC7DA070Q30498862-5B49FE1C-5534-4FE0-9DB5-BA84D5925639Q30541822-350D0105-BF02-4E8D-8DAA-DB6B993E1E39Q30856480-A89A9C80-9612-4A5F-8969-448657A573ECQ33231356-480D318C-0114-4A5F-B652-A8C78A0C4481Q33267617-BE2E4EFF-EEB2-4665-BDE4-8A608EFE55C0Q33294492-C5A779C4-E504-44DD-B98C-597286D99DE3Q33392127-7D1A0226-ECBB-44BA-8538-986D137FAD93Q33429003-0A944466-3296-4DF1-8199-39280C06098EQ33503629-048031AC-52CC-41F1-9BE2-439DB27339D4Q33627226-8A85A5FC-7FEE-45FE-8EE9-58F0B6722A5CQ33643679-5E7D009F-5720-421A-8131-446B898DD3F1Q33715640-6B04B563-CAA2-4A1A-AD1E-90A7A46F68D4Q33724346-3A57C486-8C01-4C1B-A91F-77F76BDBD493Q33746261-823E8AEB-C0A1-4BA8-B3C5-AE51709B514CQ33748087-03EA7E8E-985A-4E33-B023-0F27ED31263CQ33822641-F653870F-455B-4490-9F4A-962D33A4145FQ33831775-EE870416-0601-435E-AC78-28FEEAECBCF7Q33844949-CE948D78-381B-464A-B086-FA60725C9582Q33948478-4E578D30-A1C2-4B69-B85B-FF09FC359C2CQ34062509-6405BA48-BFEA-4FE4-B4F4-41D6AF9505F9Q34189660-7E84AAC5-4A46-49FD-9059-3B1F773CA268Q34234597-25C400B0-AA5E-41A1-BC69-6DB9AFA542B3Q34286365-91CE3433-7454-470B-AE0F-EC9F4A3E3C1A
P2860
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The formation of highly solubl ...... hanced in Parkinson's disease.
@en
type
label
The formation of highly solubl ...... hanced in Parkinson's disease.
@en
prefLabel
The formation of highly solubl ...... hanced in Parkinson's disease.
@en
P2093
P1433
P1476
The formation of highly solubl ...... hanced in Parkinson's disease.
@en
P2093
Dennis J Selkoe
Dominic M Walsh
Ifat Bar-Joseph
Matthew P Frosch
Ronit Sharon
P304
P356
10.1016/S0896-6273(03)00024-2
P407
P577
2003-02-01T00:00:00Z